SCHEMBL6216477

SCHEMBL6216477

COc1cccc(NC(=O)N[C@H](CC(C)C)[C@H](O)CN2CCC(Cc3ccc(F)cc3)CC2)c1

nearest known ligand 0.67

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 19/20 0.67
HTR2A P28223 1/20 0.62
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6216476 1.00 CCR3 (0.67) CCR3HTR2AMEN1KMT2A
SCHEMBL6218984 1.00 CCR3 (0.67) CCR3HTR2AMEN1KMT2A
SCHEMBL6216552 0.92 CCR3 (0.69) CCR3HTR2AMEN1KMT2A
SCHEMBL6216653 0.92 CCR3 (0.69) CCR3HTR2AMEN1KMT2A
SCHEMBL6216555 0.92 CCR3 (0.69) CCR3HTR2AMEN1KMT2A
SCHEMBL6216193 0.90 CCR3 (0.71) CCR3HTR2AMEN1KMT2A
SCHEMBL6216195 0.90 CCR3 (0.71) CCR3HTR2AMEN1KMT2A
SCHEMBL6216779 0.90 CCR3 (0.71) CCR3HTR2AMEN1KMT2A
SCHEMBL6216253 0.90 CCR3 (0.69) CCR3HTR2AMEN1KMT2A
SCHEMBL6213690 0.90 CCR3 (0.69) CCR3HTR2AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1158980-B1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB PHARMA CO (US) 2005-08-24 EP claimed
US-20040002515-A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity KO SOO S (US) 2004-01-01 US claimed
US-6486180-B1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-26 US claimed
US-20050192291-A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity KO SOO S (US) 2005-09-01 US disclosed
EP-1158980-B1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB PHARMA CO (US) 2005-08-24 EP disclosed
US-6875776-B2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-04-05 US disclosed
US-20040002515-A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity KO SOO S (US) 2004-01-01 US disclosed
US-6486180-B1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-26 US disclosed
EP-1158980-A4 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARM CO (US) 2002-04-03 EP disclosed
EP-1158980-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Du Pont Pharmaceuticals Company (US) 2001-12-05 EP disclosed
WO-2000035453-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002515-A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity CCR3, CCR1, CCR10 CCR3 1/4885HTR2A 1608/4885MEN1 4757/4885
US-20050192291-A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity CCR3, CCR1, ACKR3 CCR3 1/4885HTR2A 1476/4885MEN1 4797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.